Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Hou, Jue ^a   Zhang, Zili ^a   Huang, Qiang ^a   Yan, Jun ^a   Zhang, Xiaohu ^a   Yu, Xiaoliang ^a   Tan, Guihua ^a   Zheng, Chunfu ^a   Xu, Feng ^a   He, Sudan ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Anti HSV; HSV; Immediate early gene; PHA767491; Viral replication

Indexed keywords

ANTIVIRUS AGENT; DNA HELICASE; DNA POLYMERASE; DNA PRIMASE; PHA 767491; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRAL PROTEIN GB; VIRUS DNA; PIPERIDONE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA SYNTHESIS; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; GENE EXPRESSION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; ICP27 GENE; ICP4 GENE; IMMEDIATE EARLY GENE; IN VITRO STUDY; IN VIVO STUDY; LIVER TISSUE; MOUSE; NECROPTOSIS; NONHUMAN; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN ALPHAHERPESVIRUS 1; MICROBIAL SENSITIVITY TEST; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; PIPERIDONES; PYRROLES; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 85015699697     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2305-0     Document Type: Article

References (44)

1. Kaur R, Gupta N, Baveja UK. Seroprevalence of HSV-1 and HSV-2 infections in family planning clinic attenders. J Commun Dis. 2005;37:307-9.
2. Nahmias A, Roizman B. Infection with herps-simplex viruses 1 and 2.1. N Engl J Med. 1973;289:667-74.
3. Corey L, Spear PG. Infections with herps simplex viruses. N Engl J Med. 1986;314:686-91.
4. Stewart JA, Reef SE, Pellett PE, Corey L, Whitley RJ. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:114-20.
5. Pass RF, Long WK, Whitley RJ, Soong SJ, Diethelm AG, Reynolds DW, et al. Productive infection with cytomegalovirus and herps simplex virus in renal transplant recipients: role of source kidney. J Infect Dis. 1978;137:556-63.
6. Kuo YC, Lin CY, Cheng SF, Lin CC, Liu WT. Impaired natural killer cytotoxicity during recrudescence of recurrent herps simplex virus type 1 infection. Cancer Detect. 1987;1:51-5.
7. Logan WS, Tindall JP, Elson ML. Chronic cutaneous herps simplex. Arch Dermatol. 1971;103:606-14.
8. Lacasse JJ, Schang LM. During lytic infections, herps simplex virus type 1 DNA is in complexes with the properties of unstable nucleosomes. J Virol. 2010;84:1920-33.
9. Preston CM. Repression of viral transcription during herps simplex virus latency. J Gen Virol. 2000;81:1-19.
10. Balliet JW, Schaffer PA. Point mutations in herpes simplex virus type 1oriL, but not in oriS, reduce pathogenesis during acute infection of mice and impair reactivation from latency. J Virol. 2006;80:440-50.
11. Crute JJ, Mocarski ES, Lehman IR. A DNA helicase induced by herpes simplex virus type 1. Nucleic Acids Res. 1998;16:6585-96.
12. Crute JJ, Tsurumi Y, Zhu LA, Weller SK, Olivo PD, Challberg MD, et al. Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products. Proc Natl Acad Sci U S A. 1989;86:2186-9.
13. Chen Y, Bai P, Mackay S, Korza G, Carson JH, Kuchta RD, et al. Herpes simplex virus type 1 helicase-primase: DNA binding and consequent protein oligomerization and primase activation. J Virol. 2011;85:968-78.
14. Weller SK, Coen DM. Herpes simplex viruses: mechanisms of DNA Replication. Cold Spring Harb Perspect Biol. 2012. doi: 10.1101/cshperspect.a013011.
15. Deluca NA, Mccarthy AM, Schaffer PA. Isolation and Characterization of Deletion Mutants of Herpes-Simplex Virus Type-1 in the Gene Encoding Immediate-Early Regulatory Protein-Icp4. J Virol. 1985;56:558-70.
16. Rice SA, Knipe DM. Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein icp27. J Virol. 1990;64:1704-15.
17. Uprichard SL, Knipe DM. Herpes simplex ICP27 mutant viruses exhibit reduced expression of specific DNA replication genes. J Virol. 1996;70:1969-80.
18. Kimberlin D, Coen DM, Biron KK, Cohen JI, Lamb RA, Mckinlay M, et al. Molecular mechanisms of antiviral resistance. Antiviral Res. 1995;26:369-401.
19. Cirelli R, Herne K, McCrary M, Lee P, Tyring SK. Famciclovir: review of clinical efficacy and safty. Antiviral Res. 1996;29:141-51.
20. Morfin F, Thouvenot D. Herps simplex virus resistance to antiviral drugs. J Clin Virol. 2003;26:29-37.
21. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114-28.
22. Montaqnoli A, Valsasina B, Croci V, Mwnichincheri M, Rainoldi S, Marchesi V. A Cdc7 kinase inbibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008;4:357-65.
23. Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montaqnoli A, Samali A, et al. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells. Mol Cancer Ther. 2011;10:1624-34.
24. Liachko NF, McMilan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol. 2013;74:39-52.
25. Li W, Zhao XL, Shang SQ, Shen HQ, Chen X. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15:196-204.
26. Wang X, Li Y, Liu S, Yu X, Li L, Shi C, et al. Direct activation of RIP3/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense. Proc Natl Acad Sci U S A. 2015;111:15438-43.
27. He S, Liang Y, Shao F, Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci U S A. 2011;108:20054-9.
28. Festjens N, Vanden BT, Vandenabeele P. Necrosis, a well orchestrated form of cell demise: signaling cascade, important mediators and concomitant immune response. Biochim Biophys Acta. 2006;1757:1371-87.
29. He S, Wang L, Miao L, Wang T, Du F, Zhao L. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137:1100-11.
30. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, et al. RIP3, an energy metabolism regulator that swiches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325:332-6.
31. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112-23.
32. Guo H, Omoto S, Harris PA, Finger JN, Bertin J, Gough PJ, et al. Herpes simplex virus suppresses necroptosis in human cells. Cell Host Microbe. 2015;17:243-51.
33. Huang Z, Wu S, Liang Y, Zhou X, Chen W, Li L, et al. RIP1/RIP3 binding to HSV-1 ICP6 initiates necroptosis to restrict virus propagation. Cell Host Microbe. 2015;17:229-42.
34. Simmons A. Clinical manifestations and treatment considerations of herps simplex virus infection. J Infect Dis. 2002;186:71-7.
35. Lin SS, Chou MY, Ho CC, Kao CT, Tsai CH, Wang L, et al. Study of the viral infections and cytokines associated with recurrent aphthous ulceration. Microb infect. 2005;7:635-44.
36. Whitley R, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis. 1995;20:414-20.
37. Egan KP, Wu S, Wigdahl B, Jennings SR. Immunological control of herps simplex virus infections. J Neuroviral. 2013;19:328-45.
38. Steiner I, Benninger F. Update on herps virus infections of the nervous system. Curr Neurol Neurosci Rep. 2013;13:414.
39. De Oliveira A, Prince D, Lo CY, Lee LH, Chu TC. Antiviral activity of theaflavin digallate against herpes simplex virus type 1. Antiviral Res. 2015;118:56-7.
40. Amici C, Rossi A, Costanzo A, Ciafre S, Marinari B, Balsamo M, et al. Herpes simplex virus disrupts NF-ΚB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem. 2006;281:7110-7.
41. Teresa SM, Medici MA, Marino MF, Zaccaria D, Gluffre M, Venuti A, et al. Signaling pathway used by HSV-1 to induce NF-ΚB activation: possible role of herpes virus entry receptor A. Ann N Y Acad Sci. 2007;1096:89-96.
42. Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest. 2001;107:143-51.
43. Gillis PA, Okaqaki LH, Rice SA. Herpes simplex virus type 1 ICP27 induces p38 mitogen-activated protein kinase signaling and apoptosis in HeLa cells. J Virol. 2009;83:1767-77.
44. Chen D, Su A, Fu Y, Wang X, Lv X, Xu W, et al. Harmine blocks herpes simplex virus infection through downregulating cellular NF-ΚB and MAPK pathways induced by oxidative stress. Antiviral Res. 2015;123:27-38.